title: Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
abstract: Carboplatin, a clinically active analogue of cisplatin, was added to a regimen containing ifosfamide and etoposide, two agents with proven activity in non-small cell lung cancer (NSCLC). From August 1986 until November 1988, 43 consecutive patients (29 men and 14 women), mean age 57 years, performance status of 2 or less, with symptomatic, inoperable NSCLC were accrued and received carboplatin 100 mg/m2 on days 1, 3, and 5, or 300 or 350 mg/m2 on day 1; ifosfamide 1,500 mg/m2 and etoposide 60 or 100 mg/m2 every 4 weeks. Thirty-four patients were previously untreated, nine had been irradiated before, and two had also received previous chemotherapy. So far, 154 courses have been administered; 19 patients have received four or more courses. With the combination of 350 mg/m2 carboplatin and 100 mg/m2 etoposide, myelosuppression was dose-limiting; nephrotoxicity and neurotoxicity did not occur. Evaluation of response after two or four courses in 40 patients showed an objective response in 40%, whereas 30% progressed during therapy. Carboplatin added to etoposide and ifosfamide is a feasible combination that warrants further study in a randomized fashion.
authors.affiliation: The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam.
authors.forename: N
authors.initials: N
authors.lastname: van Zandwijk
authors.forename: W W
authors.initials: WW
authors.lastname: ten Bokkel Huinink
authors.forename: J
authors.initials: J
authors.lastname: Wanders
authors.forename: G
authors.initials: G
authors.lastname: Simonetti
authors.forename: R
authors.initials: R
authors.lastname: Dubbelman
authors.forename: H
authors.initials: H
authors.lastname: Franklin
authors.forename: H
authors.initials: H
authors.lastname: van Tinteren
authors.forename: J G
authors.initials: JG
authors.lastname: McVie
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: D009944:Organoplatinum Compounds; D005047:Etoposide; D016190:Carboplatin; D015080:Mesna; D007069:Ifosfamide